Company intelligence / Profile preview
Thymon
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Thymon, LLC has developed two investigational drugs targeting the HIV Tat protein for the treatment of HIV infections. BI‑201 reached clinical development but was discontinued. TUTI‑16 completed a Phase 1/2 trial in asymptomatic, well-controlled HIV patients and its status remains pending further development. There are no approved products.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Thymon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thymon.